Catalent Pharma takes over Delphi Genetics. The Gosselies BioPark will be its European Center of Excellence in Gene and Cell Therapy. Delphi Genetics is one of ULB‘s oldest spin-offs, created twenty years ago. The company, which employs around 40 people, is a pharmaceutical subcontracting company (CDMO) specializing in cell and gene therapies. Its mission is not to develop treatments,[…]
GOSSELIES, BELGIUM – February 3, 2020 — MaSTherCell S.A., a subsidiary of MaSTherCell Global, Inc., a subsidiary of Orgenesis Inc. (NASDQ: ORGS) a technology-focused cell and gene therapy contract development and manufacturing partner to leading cell therapy innovators, today announced an agreement to acquire MaSTherCell Global that has been reached between the owners of MaSTherCell Global and Catalent Pharma[…]
Through a reversible deal, MaSTherCell has been acquired by Orgenesis (a leader in the emerging fields of cellular therapy and re-generative medicine for the treatment of Type 1 Diabetes) in March 2015. MaSTherCell will be responsible for the development and the commercialization of Orgenesis’ product and will also maintain his CDMO core business activity in[…]